AIM ImmunoTech Announces Release of the Next CEO Corner Segment
AIM ImmunoTech Inc. (NYSE American: AIM) has released a new CEO Corner segment on its website. In this segment, CEO Thomas Equels discusses the positive data from the Phase 1 clinical trial that investigated an Ampligen-containing chemokine modulation therapy used in combination with the chemotherapy drug paclitaxel. The trial focused on the treatment of early stage, triple-negative breast cancer. This update provides investors with insights into the company's progress in developing potential cancer treatments and its ongoing clinical research efforts.
AIM ImmunoTech Inc. (NYSE American: AIM) ha pubblicato un nuovo segmento 'CEO Corner' sul suo sito web. In questo segmento, il CEO Thomas Equels discute i dati positivi del trial clinico di Fase 1 che ha investigato una terapia di modulazione della chemokina contenente Ampligen utilizzata in combinazione con il farmaco chemioterapico paclitaxel. Il trial si è concentrato sul trattamento del cancro al seno triplo negativo in fase iniziale. Questo aggiornamento fornisce agli investitori informazioni sui progressi dell'azienda nello sviluppo di potenziali trattamenti contro il cancro e sui suoi sforzi di ricerca clinica in corso.
AIM ImmunoTech Inc. (NYSE American: AIM) ha lanzado un nuevo segmento 'CEO Corner' en su sitio web. En este segmento, el CEO Thomas Equels discute los datos positivos del ensayo clínico de Fase 1 que investigó una terapia de modulación de quimiocinas que contiene Ampligen utilizada en combinación con el fármaco de quimioterapia paclitaxel. El ensayo se centró en el tratamiento del cáncer de mama triple negativo en etapas tempranas. Esta actualización proporciona a los inversores información sobre el progreso de la empresa en el desarrollo de posibles tratamientos contra el cáncer y sus continuos esfuerzos de investigación clínica.
AIM ImmunoTech Inc. (NYSE American: AIM)는 웹사이트에 새로운 'CEO Corner' 세그먼트를 공개했습니다. 이 세그먼트에서 CEO Thomas Equels는 암플리젠을 포함하는 화학 인자 조절 요법의 1상 임상 시험에서의 긍정적인 데이터에 대해 논의합니다. 이 요법은 화학 요법 약물인 파클리탁셀과 함께 사용되었습니다. 이 시험은 초기 단계의 삼중 음성 유방암 치료에 초점을 맞추었습니다. 이 업데이트는 투자자들에게 암 치료 개발에 대한 회사의 진행 상황 및 지속적인 임상 연구 노력에 대한 통찰을 제공합니다.
AIM ImmunoTech Inc. (NYSE American: AIM) a publié un nouveau segment 'CEO Corner' sur son site web. Dans ce segment, le PDG Thomas Equels discute des données positives de l'essai clinique de Phase 1 qui a étudié une thérapie de modulation des chimiokines contenant de l'Ampligen utilisée en combinaison avec le médicament de chimiothérapie paclitaxel. L'essai était axé sur le traitement du cancer du sein triple négatif à un stade précoce. Cette mise à jour fournit aux investisseurs un aperçu des progrès de l'entreprise dans le développement de traitements potentiels contre le cancer et de ses efforts de recherche clinique en cours.
AIM ImmunoTech Inc. (NYSE American: AIM) hat ein neues Segment 'CEO Corner' auf seiner Website veröffentlicht. In diesem Segment diskutiert CEO Thomas Equels die positiven Daten aus der Phase-1-Studie, die eine Ampligen-haltige Chemokin-Modulationstherapie in Kombination mit dem Chemotherapeutikum Paclitaxel untersucht hat. Die Studie konzentrierte sich auf die Behandlung von frühem, dreifach negativem Brustkrebs. Dieses Update bietet den Investoren Einblicke in die Fortschritte des Unternehmens bei der Entwicklung potenzieller Krebsbehandlungen und dessen laufende klinische Forschungsanstrengungen.
- Positive data from Phase 1 clinical trial for triple-negative breast cancer treatment
- Combination therapy of Ampligen with paclitaxel shows promise
- Progress in developing potential cancer treatments
- None.
OCALA, Fla., July 29, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced the next CEO Corner segment has been published on the Company’s website. In the CEO Corner segment, AIM Chief Executive Officer Thomas Equels provides an overview of the positive data from the Phase 1 clinical trial investigating an Ampligen-containing chemokine modulation therapy in conjunction with the chemotherapy drug paclitaxel in the treatment of early stage, triple-negative breast cancer.
The CEO Corner segment is now available here.
About AIM ImmunoTech Inc.
AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s lead product is a first-in-class investigational drug called Ampligen® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system.
For more information, please visit aimimmuno.com and connect with the Company on X, LinkedIn, and Facebook.
Investor Contact:
JTC Team, LLC
Jenene Thomas
(833) 475-8247
AIM@jtcir.com
FAQ
What is the latest update from AIM ImmunoTech's CEO Corner segment?
What type of cancer is AIM ImmunoTech (AIM) targeting in its recent clinical trial?
What drugs are being studied in AIM ImmunoTech's (AIM) recent Phase 1 trial?
Where can investors find AIM ImmunoTech's (AIM) latest CEO Corner segment?
